ESR1 and breast carcinoma: Such studies provided evidence that the activation of RTKs such as the epidermal growth factor receptor, HER2, and insulin-like growth factor receptor leads to the activation of ER in breast cancer independent of its ligand, thus promoting cancer cell survival and conferring resistance to antiestrogen therapy [18, 19].